Literature DB >> 30156153

Meta-analysis of Clinical Outcomes of Electrical Cardioversion and Catheter Ablation in Patients with Atrial Fibrillation and Chronic Kidney Disease.

Igor Diemberger1, Simonetta Genovesi2, Giulia Massaro1, Maria Letizia Bacchi Reggiani1, Jessica Frisoni1, Giulia Gorlato3, Erminio Mauro3, Margherita Padeletti4, Antonio Vincenti5, Giuseppe Boriani3.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is associated with adverse outcomes in presence of atrial fibrillation (AF). However, the literature shows limited data on non-pharmacological management of AF in CKD patients. AIM: summarizing the available data on outcomes associated with electrical cardioversion (ECV) and AF catheter ablation (CA) in CKD patients.
METHODS: We searched MEDLINE and the Cochrane Central Register of Controlled Trials and performed a metaanalysis. The primary outcome was recurrence of AF. The secondary outcomes were occurrence of thromboembolic events (TEs) and estimated glomerular filtration rate (eGFR) modification.
RESULTS: Literature search yielded 26 eligible papers: 22 on CA and 4 concerning ECV. CKD patients presented more AF recurrences 30 days after ECV (OR 2.62, 95%CI 1.28-5.34; p <0.001). Patients with eGFR<60-68 ml/min and on dialysis presented a higher incidence of AF recurrences after CA, median follow up 26.0 and 29.9 months (HR 1.75, 95%CI 1.46-2.09, p <0.001; and HR 1.69, 95%CI 1.22-2.33, p <0.001; respectively). Periprocedural TEs were rare and not associated with CKD or dialysis. However, patients with CKD were at increased risk for delayed TEs after CA (HR 2.61, 95%CI 1.04-6.54; p <0.001). No significant modification of eGFR was associated with ECV or CA in the overall population.
CONCLUSION: ECV and CA for sinus rhythm restoration/maintenance in AF patients, albeit theoretically promising, seem to be associated with lower efficacy at medium to long-term in patients with CKD. Further studies are needed to better define the role of ECV and CA in CKD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Electrical cardioversion; atrial fibrillation; catheter ablation; chronic kidney disease; meta-analysis; thromboembolic events (TEs).

Mesh:

Year:  2018        PMID: 30156153     DOI: 10.2174/1381612824666180829112019

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

Review 1.  Atrial fibrillation and chronic kidney disease conundrum: an update.

Authors:  Laura Tapoi; Carina Ureche; Radu Sascau; Silvia Badarau; Adrian Covic
Journal:  J Nephrol       Date:  2019-07-18       Impact factor: 3.902

2.  Chronic Kidney Disease with Mild and Mild to Moderate Reduction in Renal Function and Long-Term Recurrences of Atrial Fibrillation after Pulmonary Vein Cryoballoon Ablation.

Authors:  Giuseppe Boriani; Saverio Iacopino; Giuseppe Arena; Paolo Pieragnoli; Roberto Verlato; Massimiliano Manfrin; Giulio Molon; Giovanni Rovaris; Antonio Curnis; Giovanni Battista Perego; Antonio Dello Russo; Maurizio Landolina; Marco Vitolo; Claudio Tondo
Journal:  J Cardiovasc Dev Dis       Date:  2022-04-21

3.  The effect of concomitant chronic kidney disease on the recurrence of atrial fibrillation after catheter ablation: A protocol for systematic review and meta-analysis.

Authors:  Xiaodong Liu; Dapeng Wang; Bo Tang; Xiuying Lv
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

Review 4.  Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes.

Authors:  Giuseppe Boriani; Marco Vitolo; Igor Diemberger; Marco Proietti; Anna Chiara Valenti; Vincenzo Livio Malavasi; Gregory Y H Lip
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 13.081

5.  The efficacy and safety of amiodarone combined with beta-blockers in the maintenance of sinus rhythm for atrial fibrillation: A protocol for systematic review and network meta-analysis.

Authors:  Shuqing Shi; Qiulei Jia; Jingjing Shi; Shuai Shi; Guozhen Yuan; Yuanhui Hu
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.